David Day and a lifetime of missed moments

8 June 2018
“I couldn’t eat. Barely slept. I was the one to tell Dave it was all over. All Dave said was ‘my poor, poor babies’.” Jenny, David’s wife.
When David lost his life last year, he was 33, with three daughters under six.
David Day was one of the 20% of people with advanced melanoma have primary resistance to new drugs with ‘super progression' and we need to find out why.
The greatest challenge our clinicians currently face in treating melanoma is ‘super progression’.
Amid all our success stories, there is still a group of people with advanced melanoma for whom absolutely nothing works. About 20% of patients our medical oncologists see with advanced melanoma fall into this category.
Super progressors do not respond to existing treatments. Within a few short months, their disease progresses aggressively and relentlessly and we cannot save them.
David Day, was one such patient —a lovely young father with a wonderful family — who died last year.
The most agonising thing about patients like David is that at present, we just don’t know why they super progress.
Dr Inês Silva was part of the clinical team which treated David Day. She was studying at MIA as a Medical Oncology Fellow from Portugal. David had such a profound impact on Inês, that on completion of her Fellowship, she decided to stay on at MIA as a Research Scientist in an all-out attempt to find answers for super progressors.
Inês and the MIA research team collected blood and melanoma tissue samples from David during his treatment. They also collected similar samples from other advanced melanoma patients who have not responded to immunotherapy.
By studying the genomic profile and protein expression in each of these patients’ tumours, Ines and the MIA research team hope to understand why each drug failed to work, paving the way for new, and potentially life-saving therapies.
While there is some existing grant funding to cover her salary, a dedicated Research Scientist like Inês can’t do it alone.
We are relying on you and on the support of our donor community to collectively fund this research project including research assistants’ salaries, PhD student scholarship top-ups, equipment, and state-of-the-art research technologies such as DNA, RNA and cell sequencing. All are key to understanding and solving primary resistance and super progression.
David was a sweet, humble family man. He was a high-achiever, had forged an exceptional career as a computer engineer for Google and made a loving, happy life raising his three daughters Charlotte, 7, Emma, 5, and Annie, now 1, with his wife Jenny, his childhood sweetheart since Year 9.
Just before Christmas 2016, with Jenny heavily pregnant with little Annie, Dave found a lump under his left arm. He had Stage III melanoma. Half way through his treatment, David found another lump under his arm and a new tumour was discovered on his left hip. His melanoma had progressed to Stage IV.
In March 2017, David and Jenny were referred to Melanoma Institute Australia. He started on a clinical trial and at first, his scans looked promising.
After starting treatment, another painful melanoma appeared on David’s wrist. In the next three months, tumours sprang up in his spleen, lungs, pancreas, bones, under his skin — with up to 30 more in his liver. Even though immune cells were present, David was super progressing.
As the months passed, David suffered extreme pain, liver damage, rapid weight loss, blurred vision and internal bleeding. The clinical team switched to chemotherapy as a last resort and Annie’s christening was pushed forward.
On 25 August 2017, Jenny had the worst imaginable task of explaining to her soul mate that nothing more could be done for him.
“I was the one to tell him it was over. All he could say was “My poor, poor babies”. My heart ached. I had lost 15kg over the past five months from the stress of the whole situation. My milk dried up and I couldn’t feed Annie. It ate away at me while I put on a brave face for Dave and the kids,” says Jenny.
Jenny has very generously shared her painful story in the hope that it will help raise funds to crack the riddle of super progression.
Please give today to save someone you know from the ravages of melanoma in the future, and give them what David didn’t have- the opportunity to enjoy a lifetime of special moments with their loved ones.

Melanoma March has officially launched
Melanoma Institute Australia (MIA) has officially launched the 2015 ‘Melanoma March’ initiative in Melbourne.

Melanoma March is around the corner
Help us march towards a cure for melanoma research. See where your local march is and how you can get involved.

Q&A with a PhD student
Under the leadership of world-leading melanoma pathologist Prof Richard Scolyer and medical oncologist A/Prof Georgina Long, third year PhD student, Hojabr Kakavand, is at the forefront of melanoma research.

ClinTrial Refer Melanoma App
Melanoma Institute Australia has launched a new smartphone app called ClinTrial Refer Melanoma to help busy clinicians find clinical trials for their melanoma patients.

Interview on the latest melanoma treatments
MIA's Associate Professor Georgina Long and stage 4 melanoma patient, Maria, were recently interviewed by ABC Weekend Breakfast about the latest in clincial trials and melanoma treatments.

Sunbed campaigner acknowledged as one of most influential Australians
Sunbed campaigner, Jay Allen, has been acknowledged on the honour roll of Australia’s most influential people in the non-profit sector.

A world-class organisation needs a world-class website
Today we launch the website we’ve dreamed about!

Watch Your Mate's Back kicks off soon
Our new summer campaign has you and your mates' backs covered!

Saving our next generation
Researcher James Wilmott is working to fill a gap in research for young patients.

It's time to march for a cure!
Join us for our fourth annual Melanoma March and help us raise over $1 million for melanoma research as we march for a cure!

Making a difference
When Melanoma Institute Australia (MIA) patients at the Poche Centre are first diagnosed with advanced melanoma Anna Hoadley is there.

New trial offers hope to Stage IV patients
Shining new hope for patients with advanced stage melanoma.

Combination drug therapy halts disease in advanced melanoma
A world-first study in the New England Journal of Medicine heralds the effectiveness of a targeted combination drug therapy after reporting major declines in the risk of disease progression and death in people with metastatic melanoma.

Georgina Long wins award for Outstanding Cancer Research
Associate Professor Georgina Long wins award for Cancer Institute NSW

Melanoma survivors walk from Sydney to Melbourne to raise money
Melanoma survivors and long-time friends Jay Allen and Andrew Rust concluded their 900km walk from Sydney to Melbourne completing their walk at the Melbourne Cricket Ground on Saturday 26 July.

The Federal Government's 2015-16 Budget announcements benefit research
The Federal Government’s 2015-16 Budget was announced this week with a boost for medical research funding.
Melanoma Essentials eBook offered for Free during EADO and GAC (PDF)
Melanoma Essentials eBook offered for Free during EADO and GAC

It's 'Game On Mole' this summer! - Copy
All Australians are urged to join the fight against melanoma this summer.
It's 'Game On Mole' this summer!
All Australians are urged to join the fight against melanoma this summer.